(Q41475106)

1 October 2017

1 reference

title

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases (English)

1 reference

1 October 2017

Segal BH

1

1 reference

1 October 2017

Sneller MC

series ordinal

2

1 reference

1 October 2017

publication date

1 May 1997

1 reference

Rheumatic Diseases Clinics of North America

1 October 2017

published in

1 reference

1 October 2017

volume

23

1 reference

1 October 2017

issue

2

1 reference

1 October 2017

page(s)

219-237

1 reference

Alternate-day steroid therapy in lupus nephritis

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Immunologic effects of cyclophosphamide treatment in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Pulmonary involvement in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Alternate-day single-dose prednisone therapy: A method of reducing steroid toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Infections during low-dose methotrexate treatment in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Infectious complications of cyclophosphamide treatment for vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

A Controlled Trial of Cyclophosphamide in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Alternate-day corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

The Effect of In Vivo Hydrocortisone on Subpopulations of Human Lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Glucocorticosteroid therapy: mechanisms of action and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

NIH conference. Recent advances in chronic granulomatous disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Pancytopenia from using trimethoprim and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

The effect of azathioprine on gammaglobulin synthesis in man

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

IMMUNOLOGIC RESPONSES OF HEALTHY VOLUNTEERS RECEIVING AZATHIOPRINE (IMURAN)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Prevention and treatment of pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Cytomegalovirus pneumonia in adult nontransplantation patients with cancer: review of 20 cases occurring from 1964 through 1990.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Neurological complications of vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Immunologic studies of rheumatoid arthritis patients treated with methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Rapid detection of cytomegalovirus pneumonia from lung lavage cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Effects of corticosteroids on human monocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

The mechanism of action of cyclosporin A and FK506

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Lack of effect of azathioprine on phytohemagglutinin-induced lymphocyte transformation and established delayed cutaneous hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Prednisone-induced leukocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Reduction of toxicity of corticosteroid therapy after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Effect of immunosuppressive therapy on the clinical presentation and outcome of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Psoriasis, methotrexate and tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Fever in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Incidence of infection in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Risk of infectious complications in patients taking glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-857X%2805%2970327-6

7 January 2021

10.1016/S0889-857X(05)70327-6

Identifiers

DOI

1 reference

1 October 2017

1 reference